Hostname: page-component-78c5997874-94fs2 Total loading time: 0 Render date: 2024-11-10T20:43:24.567Z Has data issue: false hasContentIssue false

Use of benzodiazepines and cognitive performance in primary care patients with first cognitive complaints

Published online by Cambridge University Press:  10 November 2017

G. Grande*
Affiliation:
Center for Research and Treatment on Cognitive Dysfunctions, Biomedical and Clinical Sciences Department, “Luigi Sacco” Hospital, University of Milan, Milan, Italy Aging Research Center, Department of Neurobiology, Care Sciences, and Society (NVS), Karolinska Institutet and Stockholm University, Stockholm, Sweden
I. Tramacere
Affiliation:
Unit of Neuroepidemiology, I.R.C.C.S. Foundation, Carlo Besta Neurological Institute, Milan, Italy
D. L. Vetrano
Affiliation:
Aging Research Center, Department of Neurobiology, Care Sciences, and Society (NVS), Karolinska Institutet and Stockholm University, Stockholm, Sweden Department of Geriatrics, Catholic University of Rome, Rome, Italy
S. Pomati
Affiliation:
Center for Research and Treatment on Cognitive Dysfunctions, Biomedical and Clinical Sciences Department, “Luigi Sacco” Hospital, University of Milan, Milan, Italy
C. Mariani
Affiliation:
Center for Research and Treatment on Cognitive Dysfunctions, Biomedical and Clinical Sciences Department, “Luigi Sacco” Hospital, University of Milan, Milan, Italy
G. Filippini
Affiliation:
Scientific Direction, I.R.C.C.S. Foundation, Carlo Besta Neurological Institute, Milan, Italy
*
Correspondence should be addressed to: Giulia Grande, MD PhD candidate, Aging Research Center | Karolinska Institutet, Gävlegatan 16, 11330 Stockholm, Sweden. Phone: +46 8 690 6853; Fax: +46 8 6906889. Email: giulia.grande@ki.se.

Abstract

The aim of the present study is to investigate the impact of benzodiazepine use on cognitive performance in primary care patients with first cognitive complaints. The association between the exposition to benzodiazepines (short and long half-life) and cognitive performance, evaluated through the Mini Mental State Examination (MMSE), was tested through analysis of the covariance and logistic regression models. Within the 4,249 participants (mean age 77.0 ± 8.2, 66.4% women), 732 (17%) were on benzodiazepines. When compared with non-users, short- and long-acting benzodiazepine users presented overlapping adjusted MMSE mean scores (respectively, mean MMSE score: 25.3, 95%CI 25.2–25.5; 25.4, 95%CI 25.1–25.7, and 25.9, 95%CI 25.3–26.4; p = 0.156). When tested according to the logistical regression model, after adjusting for potential confounders, no association was found between short and long acting benzodiazepine use and a MMSE < 24 (respectively, OR 0.9, 95%CI 0.7–1.2; OR 0.8, 95%CI 0.7–1.3) as compared with non-users. In conclusion, according to the results of our study, benzodiazepine use seems not to impact on cognitive performance- as assessed with the MMSE- of primary care patients referring to GPs for first cognitive complaints.

Type
Brief Report
Copyright
Copyright © International Psychogeriatric Association 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Barker, M. J., Greenwood, K. M., Jackson, M. and Crowe, S. F. (2004). Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs, 18, 3748.Google Scholar
Billioti De Gage, S. et al. (2014). Benzodiazepine use and risk of Alzheimer's disease: case-control study. BMJ, 349, g5205.Google Scholar
Creavin, S. T. et al. (2016). Mini-Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations. Cochrane Database Systematic Reviews, doi: 10.1002/14651858.CD011145.pub2Google Scholar
Fastbom, J., Forsell, Y. and Winblad, B. (1998). Benzodiazepines may have protective effects against Alzheimer disease. Alzheimer Disease Associated Disorders, 12, 1417.CrossRefGoogle ScholarPubMed
Folstein, M. F., Folstein, S. E. and Mchugh, P. R. (1975). “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, 189–98.Google Scholar
Grande, G. et al. (2017). Role of anticholinergic burden in primary care patients with first cognitive complaints. European Journal of Neurology, 24, 950955.CrossRefGoogle ScholarPubMed
Gray, S. L. et al. (2016). Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study. BMJ, 352, i90.Google Scholar
Jessen, F. et al. (2014). A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dementia, 10, 844852.Google Scholar
Kurko, T. A. et al. (2015). Long-term use of benzodiazepines: definitions, prevalence and usage patterns - a systematic review of register-based studies. European Psychiatry, 30, 10371047.CrossRefGoogle ScholarPubMed
Lagnaoui, R. et al. (2002). Benzodiazepine use and risk of dementia: a nested case-control study. Journal of Clinical Epidemiology, 55, 314318.Google Scholar
Landi, F. et al. (2005). Psychotropic medications and risk for falls among community-dwelling frail older people: an observational study. J Gerontology A Biological Sciences and Medical Sciences, 60, 622626.Google Scholar
Measso, G..Cavarzeran, F., Zappalà, G., Lebowitz, B.D., Crook, T.H., Pirozzolo, F.J., et al. (1993). The mini-mental state examination: normative study of an Italian random sample. Developmental Neuropsychology, 9, 7785.Google Scholar
Mitchell, A. J. (2009). A meta-analysis of the accuracy of the mini-mental state examination in the detection of dementia and mild cognitive impairment. Journal of Psychiatric Research, 43, 411431.Google Scholar
O'bryant, S. E. et al. (2008). Detecting dementia with the mini-mental state examination in highly educated individuals. Archives of Neurology, 65, 963967.Google Scholar
Pariente, A., Dartigues, J. F., Benichou, J., Letenneur, L., Moore, N. and Fourrier-Reglat, A. (2008). Benzodiazepines and injurious falls in community dwelling elders. Drugs Aging, 25, 6170.CrossRefGoogle ScholarPubMed
Pariente, A., De Gage, S. B., Moore, N. and Begaud, B. (2016). The benzodiazepine-dementia disorders link: current state of knowledge. CNS Drugs, 30, 17.Google Scholar
Shash, D. et al. (2016). Benzodiazepine, psychotropic medication, and dementia: a population-based cohort study. Alzheimers Dementia, 12, 604613.Google Scholar